olaparib
astrazeneca,merck
['vance', 'solo1', 'olaparib', 'ovarian', 'medsir']
at 7-year fu of phase 3 solo1 trial, 67.0% of olaparib pts vs. 46.5% of pbo pts were alive. maintenance therapy of olaparib in bracm newly diagnosed advanced ovarian cancer pts provided a meaningful improvement in os with no new safety signals. talk by dr. disilvestro. #esmo2022 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM